首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1503153篇
  免费   111813篇
  国内免费   2484篇
耳鼻咽喉   21228篇
儿科学   50588篇
妇产科学   39955篇
基础医学   214476篇
口腔科学   40165篇
临床医学   130040篇
内科学   307525篇
皮肤病学   33857篇
神经病学   120937篇
特种医学   57725篇
外国民族医学   715篇
外科学   225328篇
综合类   28066篇
现状与发展   1篇
一般理论   457篇
预防医学   116118篇
眼科学   32230篇
药学   111215篇
  2篇
中国医学   3062篇
肿瘤学   83760篇
  2021年   11227篇
  2019年   13313篇
  2018年   20732篇
  2017年   15001篇
  2016年   16015篇
  2015年   18452篇
  2014年   23763篇
  2013年   36325篇
  2012年   53824篇
  2011年   55816篇
  2010年   31567篇
  2009年   28525篇
  2008年   51649篇
  2007年   55231篇
  2006年   54341篇
  2005年   53059篇
  2004年   51054篇
  2003年   48621篇
  2002年   47197篇
  2001年   68132篇
  2000年   70863篇
  1999年   59780篇
  1998年   15219篇
  1997年   13703篇
  1996年   14052篇
  1995年   13983篇
  1994年   13251篇
  1993年   12213篇
  1992年   46598篇
  1991年   45386篇
  1990年   43975篇
  1989年   41727篇
  1988年   38438篇
  1987年   37654篇
  1986年   34951篇
  1985年   33533篇
  1984年   25134篇
  1983年   21077篇
  1982年   12256篇
  1981年   11085篇
  1979年   22164篇
  1978年   15412篇
  1977年   13056篇
  1976年   12136篇
  1975年   13209篇
  1974年   15393篇
  1973年   14849篇
  1972年   13599篇
  1971年   12335篇
  1970年   11629篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
3.
Oral squamous cell carcinomas (OSCCs) develop in genetically altered epithelium in the mucosal lining, also coined as fields, which are mostly not visible but occasionally present as white oral leukoplakia (OL) lesions. We developed a noninvasive genetic assay using next-generation sequencing (NGS) on brushed cells to detect the presence of genetically altered fields, including those that are not macroscopically visible. The assay demonstrated high accuracy in OL patients when brush samples were compared with biopsies as gold standard. In a cohort of Fanconi anemia patients, detection of mutations in prospectively collected oral brushes predicted oral cancer also when visible abnormalities were absent. We further provide insight in the molecular landscape of OL with frequent changes of TP53, FAT1 and NOTCH1. NGS analysis of noninvasively collected samples offers a highly accurate method to detect genetically altered fields in the oral cavity, and predicts development of OSCC in high-risk individuals. Noninvasive genetic screening can be employed to screen high-risk populations for cancer and precancer, map the extension of OL lesions beyond what is visible, map the oral cavity for precancerous changes even when visible abnormalities are absent, test accuracy of promising imaging modalities, monitor interventions and determine genetic progression as well as the natural history of the disease in the human patient.  相似文献   
4.
5.
6.
7.
8.
9.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
10.
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号